A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)James R. Berenson, Robert Vescio, Tanya M. Spektor et al.|Blood|2019Cited by 2